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Abstract
Cardiovascular diseases are the primary cause of mor­
tality in the industrialized world, and arterial obstruction, 
triggered by rupture­prone atherosclerotic plaques, lead 
to myocardial infarction and cerebral stroke. Vulnerable 
plaques do not necessarily occur with flow-limiting ste­
nosis, thus conventional luminographic assessment of 
the pathology fails to identify unstable lesions. In this 
review we discuss the currently available imaging mo­
dalities used to investigate morphological features and 
biological characteristics of the atherosclerotic plaque. 
The different imaging modalities such as ultrasound, 
magnetic resonance imaging, computed tomography, 
nuclear imaging and their intravascular applications are 
illustrated, highlighting their specific diagnostic poten­
tial. Clinically available and upcoming methodologies are 
also reviewed along with the related challenges in their 
clinical translation, concerning the specific invasiveness, 
accuracy and cost­effectiveness of these methods.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
In 2007, more than 2200 Americans died of  cardiovas-
cular diseases each day; in particular, stroke accounted 
for 1 in every 18 deaths, while an estimated 1 person per 
minute died from myocardial infarction, as reported by 
the latest statistics of  the American Heart Association[1]. 
The major cause of  stroke is cerebral blood vessel block-
age as a consequence of  atherosclerotic plaque rupture in 
carotid arteries; similarly, myocardial infarction is strongly 
related to coronary artery narrowing as a consequence of  
atherosclerosis[2].
Pathogenesis of the atherosclerotic plaque: Biological 
and functional key features
Atherosclerosis is a systemic arterial inflammatory disease 
initiated by the accumulation of  fatty streaks within the 
arterial wall, which may evolve into a cholesterol-rich le-
sion hardened by the presence of  proliferating smooth 
muscle cells (SMCs); these types of  lesions are called 
atheromas[3]. Physiologically, the arterial wall consists of  
three layers, starting from the exterior: tunica adventitia 
(collagen and fibres), tunica media (SMCs and elastic fi-
bres), and tunica intima [endothelial cells (ECs), lining the 
lumen of  all vessels].
Mechanoreceptors on the surface of  ECs sense blood-
flow-induced shear stress on the arterial lumen and tran-
smit a stimulus to the nuclei through the cytoskeleton, 
inducing the intracellular signalling cascade[4-6] that even-
tually leads to alteration in the physical properties of  
ECs[7]. Consequently, intravascular low density lipopro-
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teins (LDL) and circulating monocytes can migrate below 
the intimal layer and may coalesce to form larger beds of  
fatty streaks, rich in cholesterol crystals. Additionally, fi-
bres and SMCs, physiologically present where cholesterol 
accumulates can proliferate leading to plaque formation 
and growth[3]. 
A plaque could then develop into a fibrous cap ath-
eroma, consisting of  a large necrotic core rich in extracel-
lular lipid, cholesterol crystals and necrotic debris covered 
by a fibrous cap. 
The cap is constituted by SMCs in a collagen-pro-
teoglycan matrix, with infiltrated macrophages and T 
lymphocytes[3]. Inflammatory cells are also present in 
the shoulder of  the plaque, at the interface with the 
underlying necrotic core. Highly calcified stable lesions 
or the development of  mural haemorrhage are possible 
evolutions of  the fibrous cap atheroma[3]. Moreover, T 
cells encountering antigens, such as Oxidized LDL and 
cytokines, induce macrophage activation, superoxide 
production, up-regulation of  vascular cell adhesion mol-
ecule (VCAM)-1 and protease activity, via up-regulation 
of  matrix metalloproteases (MMPs) expression, favour-
ing matrix degradation, hence the transition from stable 
plaque to thin fibrous cap atheroma (TFCA), which is 
unstable and at risk of  rupture[8]. Because atherosclerosis 
is a systemic disease, diagnostic imaging can be used to 
study arteries outside the heart such as the carotid artery 
and aorta, which are more accessible and suitable for the 
limited spatial resolution of  most imaging techniques; 
for instance, cap thickness of  the TFCA is usually lower 
than 200 μm when it occurs in the carotid artery bifurca-
tion and is 65 μm when found in the coronary artery[9]. 
Increased neovascularisation within the atherosclerotic 
plaque and fibrous cap is a further marker of  symptom-
atic carotid disease. The newly formed vasculature has 
larger and more irregular microvessels then the physi-
ologic vasa vasorum and may contribute to plaque insta-
bility and to the onset of  thromboembolic sequelae[10]. 
Immature and dysmorphic microvessels are recognized as 
sites of  vascular leakage and inflammation; nonetheless 
these vessels may be therapeutic targets for promoting 
plaque stabilization[11]. However, the vessels exhibiting 
TFCA do not necessarily show severe narrowing, but do 
have positive external remodelling[9] (Figure 1). 
The latter represents a compensation strategy to re-
store physiological levels of  blood flow velocity when 
intima thickness occurs. Conventionally, low shear stress 
regions, such as arterial bifurcations and bends, are as-
sociated with plaque formation, whereas localized high 
shear stress has been linked to plaque rupture[12,13]. None-
theless, evidence of  plaque rupture occurring in a region 
of  extremely low wall shear stress located downstream of  
the throat of  a stenotic carotid bifurcation[14,15] contrib-
utes to undermine the consensus regarding the conven-
tional association between shear stress values and plaque 
vulnerability; recent studies converge on the hypothesis 
that vulnerability is related to the mechanical Von Mises 
stress (typically five orders of  magnitude larger than wall 
shear stress) borne by the fibrous cap, to its thickness, to 
arterial remodelling and to the morphological distribution 
of  the necrotic core and other plaque components[16]. 
Moreover, biomechanical studies have shown that intimal 
tears in coronary arteries often occur at the interface of  
calcified and adjacent to non-calcified arterial tissues[17], 
thus it is likely that calcification plays an active role in 
plaque rupture. 
Different methodologies have been developed to 
directly image atherosclerosis, either invasively or non-
invasively. In 1959, Sones et al[18,19] performed the first se-
lective coronary angiography, and this rapidly became the 
technique of  choice for enabling the operator to observe 
narrowing in the arterial lumen and clinically assess the 
effects of  atherosclerosis. However, angiography is an ex-
clusively luminographic technique, providing no informa-
tion on the extent of  the disease in the arterial wall. For 
this reason, computed tomography (CT) and positron 
emission tomography (PET) are required to investigate 
the lesion composition. Both techniques involve ionizing 
radiation, potentially producing biological side effects 
with different classes of  clinical features. Later develop-
ments in diagnostic imaging techniques, such as B-mode 
Ultrasound and magnetic resonance imaging (MRI), allow 
non-ionizing imaging of  the arterial wall and eventually 
the assessment of  its pathological status. The diagnostic 
imaging techniques employed for atherosclerotic plaque 
analysis can be graded on their level of  invasiveness (Fig-
ure 2), and in this review, they are presented from the less 
hazardous to the most health threatening.
NON INVASIVE ATHEROSCLEROTIC 
PLAQUE ASSESSMENT
Non-invasive assessment of  atherosclerosis targets popu-
lations at risk of  cardiovascular disease and asymptomatic 
patients who have not yet presented with an acute cardio-
vascular event. Completely non-invasive diagnostic imag-
ing modalities are those examinations performed without 
percutaneous access to the vessel and employing non-
ionizing radiation. Non-ionizing radiation is described 
as a series of  energy waves of  different nature, such as 
oscillating electric or magnetic fields, sound waves and in-
cludes the spectrum of  ultraviolet, visible light, infrared, 
microwave, radio frequency (RF), and extremely low fre-
quency. The crucial morphological and biological features 
that characterize atherosclerotic plaques can be specifi-
cally addressed by non-ionizing diagnostic criteria using 
non-invasive imaging modalities (Table 1). 
Conventional and IB ultrasound 
In modern clinical practice, vessel outline reconstruction 
is one of  the most validated and employed applications 
of  ultrasonography (US), also supported by optimized 
tracking devices; in particular, because of  their acces-
sibility, carotid arteries represent the ideal site for clinical 
examinations[20]. In addition, the increase in intima-media 
thickness (IMT) of  the common carotid artery can be a 
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consequence of  arterial aging and hypertension and may 
identify with one of  the earliest stages of  atherosclero-
sis, as large IMT is associated with cardiovascular and 
total mortality risk[21] and could predict cardiovascular 
events in patients with coronary artery disease[22] as well 
as in asymptomatic patients[23]. IMT is usually measured 
manually on longitudinal B-mode ultrasound images, but 
many computer-based techniques for IMT measurement 
have been proposed to overcome the limits of  manual 
segmentation and measurements, most requiring a certain 
degree of  user interaction[24-26]. Despite the widespread 
use of  carotid IMT, it provides only limited information 
about the atherosclerotic process occurring distally, i.e. at 
the bifurcation or at the internal carotid, under different 
hemodynamic conditions. The latter are evaluated using 
Multigate Doppler systems in order to provide accurate 
estimates of  the distribution of  spectral Doppler com-
ponents within human arteries, and real-time processing 
of  all the echo signals produced along an M-line is also 
possible[27,28]. M-mode ultrasound records motion of  the 
interfaces toward and away from the transducer, hence 
real-time measurement of  arterial wall distension can be 
analysed through specific 2-D autocorrelation algorithms, 
whose results can be displayed in real-time to enhance 
the accuracy of  diagnosis even over long acquisitions[29]. 
Although preliminary attempts at tissue characterisa-
tion from conventional B-mode US were conducted with 
encouraging high retrospective accuracy[30], the introduc-
tion of  advanced analysis of  the backscattered US signal, 
namely integrated backscatter (IB) analysis, enabled the 
different plaque components to be distinguished based on 
their specific spectral content[31]. Integrated backscatter ul-
trasonography (IB-US) methodologies allow non-invasive 
evaluation of  the tissue substructure in human plaques by 
means of  offline data processing techniques, that improve 
the poor spatial resolution on conventional US up to 300 
μm. Compared with histology, the sensitivity and specific-
ity for detecting thrombi, lipid pools and fibrous tissue 
ranged between 80%-85% and 78%-91%, respectively, 
with peak accuracy in the detection of  calcified regions 
(sensitivity: 89%; specificity: 91%) (Figure 3)[32].
Contrast-enhanced ultrasound
Based on clinical observations and published reports, 
the presence of  neovascularisation, characterized by high 
permeability, appears to be a distinct marker of  plaque 
instability and vulnerability[10,33]. Contrast-enhanced ultra-
sonography (CE-US) relies on the detection of  acoustic 
signals produced by microbubbles that are targeted to the 
sites of  disease. Because they contain gas and are smaller 
than the wavelength of  ultrasound, these agents undergo 
volumetric oscillation in an acoustic field, thereby com-
pressing and expanding according to the acoustic pres-
sure peaks and nadirs, respectively[34]. To improve in vivo 
stability, ultrasound contrast agents commonly contain 
inert gases that have low diffusion and low solubility co-
efficients in blood. CE-US techniques may serve to char-
acterize intra-plaque angiogenesis[35], which is unrelated 
to the degree of  stenosis[36]. Specifically, a retrospective 
study of  147 patients with symptomatic carotid athero-
sclerosis demonstrated how the presence and degree of  
adventitial vasa vasorum and plaque neovascularisation 
were directly associated with cardiovascular diseases and 
events, and could be assessed by means of  contrast-en-
hanced ultrasound[37] down to the scale of  the microves-
sel[38]. Additionally, a preliminary report suggests that 
microbubbles may also be useful in quantifying plaque 
inflammation within the plaque[39].
Table 1  Plaque feature identification through non-invasive 
diagnostic imaging (without using ionizing radiation)
US CE-US MRI CE-MRI
Morphology features
Outward remodelling -1 -1 -1 -1
Plaque burden -2 [39]1 -1 -1
Lipid pool [32]1 -2 [50]1 [57]1
Necrotic core [30]1 -2 [53]1
Composition
Fibro-fatty -2 -2 [50]1 [57]1
Fibrous plaque [32]1 -2 -1 -1
Dense calcium [32]1 -2 [50]1 [58]1
Biological features
Inflammation -2 [39]1 [57]1 [60]1
Macrophage infiltration -2
Neo-angiogenesis -2 [36]1 -2 [59]1
TFCA -2 -2 [50]1 [142]1
TFCA  + MI -2 -2 -2 -2
1Limited clinical experience; 2research in progress. US: Ultrasound; CE-US: 
Contrast-enhanced ultrasound; MRI: Magnetic resonance imaging; CE-
MRI: Contrast-enhanced magnetic resonance imaging; MI: Macrophage 
infiltration; TFCA: Thin fibrous cap atheroma.
Fibrous cap
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and cytokine
Neovessel
Hemorrhage
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Figure 1  Scheme of the thin fibrous cap atheroma. Main cellular compo-
nents characterizing atherosclerotic plaque formation and destabilization are 
illustrated as well as biological and morphological features occurring in vulner-
able plaque. SMCs: Smooth muscle cells; LDL: Low density lipoprotein; MMPs: 
Matrix metalloproteases.
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Figure 2  Illustration of the invasiveness of the possible plaque imaging modalities along with the reasons of their grading. MRI: Magnetic resonance imag-
ing; IB-US: Integrated backscatter ultrasound; CE-US: Contrast enhanced ultrasound; CE-MRI: Contrast enhanced magnetic resonance imaging; CT: Computed to-
mography; CE-CT: Contrast enhanced computed tomography; SPECT: Single proton emission computed tomography; PET: Positron emission tomography; US-E: Ul-
trasound elastography; IVMRI: Intravascular magnetic resonance imaging; OCT: Optical coherence tomography; VH: Virtual histology; IVUS: Intravascular ultrasound.
Figure 3  Example of plaque characterization trough integrated backscatter ultrasonography. A: Large plaque (arrow); A1: An integrated backscatter (IB) im-
age at autopsy; A2: A color-coded map constructed from A1, based on the five IB categories and conventional 2D echo findings; A3: van Gieson staining of the same 
segment as the IB measurement (bar = 1 mm); B: Intimal fibrosis (arrow); B1: An IB image during life; B2: A color-coded map constructed from B1; B3: Masson’s 
trichrome staining of the same segment; C: Intimal hyperplasia consisting of smooth muscle cells (arrow); C1: An integrated backscatter image during life; C2: A color-
coded map constructed from C1; C3: Masson’s trichrome staining of the same segment (reprint with permission)[32].
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Different US contrast agents, such as echogenic im-
munoliposomes (ELIP) conjugated with different prote-
ases, have also been employed for the in vivo imaging of  
specific molecular expression in swine with induced endo-
thelial lesions. The selective enhancement of  endothelial 
injury/atheroma components in the presence of  the func-
tionalized ELIPs was confirmed by immunohistochem-
istry staining[11]. Thrombus-targeted microbubbles for 
CE-US conjugated with tirofiban - a glycoprotein Ⅱb/ 
Ⅲa antagonist - can specifically bind to activated platelets 
in the thrombus; the capability of  enhancing both the 
image contrast and thrombolysis, obtained as an effect 
of  microbubble US cavitation, has been investigated 
with good results compared to the non-bound contrast 
agent[40]. Recent developments in nanoparticles (NPs) 
have demonstrated their potential higher safety, due to 
their physical stability, and the same molecular specificity; 
in particular, low dose silica NPs are detectable with high 
sensitivity in experimental studies[41,42]. 
MRI
MRI of  atherosclerosis can provide information on both 
plaque volume and composition in the different arterial 
districts. Recent developments in coil and MRI sequence 
design[42,43] allow in vivo imaging of  carotid artery plaques 
with a spatial resolution of  300 μm at 1.5 Tesla[44,45]. 
Additionally, the introduction of  multispectral imaging 
allowed the characterisation of  pathological plaque com-
ponents (Figure 4), discrimination of  the lipid core, the 
fibrous cap, calcification, haemorrhage and thrombus 
with sensitivity and specificity values of  76%-92% and 
65%-86%, respectively[46-50]. Direct thrombus imaging is 
possible with specially optimized T1 weighted magneti-
zation-prepared 3-dimensional rapid acquisition gradient 
echo (MP-RAGE) sequences, that comprise an inversion 
recovery RF pulse for magnetization preparation and a 
fast gradient echo acquisition sequence[51]. With the inver-
sion time properly selected, a strong T1 weighting can be 
achieved, effectively detecting haemorrhage as proved in 
clinical studies[52].
A new slab-selective phase-sensitive inversion-reco-
very (SPI) technique is also promising improvements 
in the imaging of  intraplaque haemorrhage[53]. SPI se-
quences were compared with MP-RAGE and evaluated 
both ex vivo and in vivo for discriminating intraplaque 
haemorrhage and arterial wall; SPI had better intraplaque 
haemorrhage identification accuracy (P < 0.01) and a sig-
nificantly higher intraplaque haemorrhage-wall contrast-
to-noise ratio than MP-RAGE[53]. Further examples of  
clinical results of  MRI plaque imaging application in 
symptomatic patients with different degrees of  carotid 
stenosis were provided in a study of  the association bet-
ween plaque characteristics, cardiovascular risk factors 
and statin use by means of  plaque 1.5-T MRI (sequences 
T2W                          PDW                               T1W                           TOF                              HE                    HE          Mallory's trichrome
Figure 4  Example of histological validation of magnetic resonance imaging at four consecutive locations spanning the bifurcation. Multiple histological 
sections (at 0.5-1.0 mm-separation) generally correspond to each 2-mm thick image. Contours have been drawn for lumen (red), outer wall (cyan), lipid-rich/necrotic 
core (yellow), calcification (black), loose fibrous matrix (pink/white) and hemorrhage (orange)[49]. TOF: Time-of flight; HE: Hematoxylin and eosin; PDW: Proton density 
weighted; T2W: T2-weighted; T1W: T1-weighted.
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used were: 3-dimensional T1-weighted turbo field echo, 
3-dimensional time-of-flight, 2-dimensional T2-weighted 
turbo spin-echo, and pre- and postcontrast 2-dimen-
sional T1-weighted turbo spin-echo images). Statin use 
was positively associated with the percentage of  fibrous 
tissue within the plaque, and evidence suggests that 
symptomatic patients with moderate stenosis have a 
higher prevalence of  complicated plaques than patients 
with mild stenosis[54]. The use of  higher magnetic field 
strength for evaluating possible atherosclerotic plaque 
progression is also documented. In particular, a cohort 
of  patients with symptomatic and asymptomatic carotid 
plaques, presenting with recent intraplaque haemorrhage, 
underwent 3.0-Tesla MRI over a period of  18 mo[55]. MR 
sequences included three-dimensional time-of  flight (3D-
TOF), quadruple-inversion-recovery T1WI (QIR-T1WI), 
proton density-weighted imaging (PDWI), and T2-wei-
ghted imaging (T2WI). The contrast-to-noise ratio of  
intraplaque haemorrhage showed a significant difference 
between the haemorrhages found in symptomatic and 
asymptomatic carotid plaques on 3D-TOF (P = 0.029), 
QIR-T1WI (P = 0.005), and PDWI (P = 0.028), but not 
on T2WI (P = 0.362). Symptomatic intraplaque haemor-
rhage displayed no significant change in signal intensity, 
whilst asymptomatic intraplaque haemorrhage contrast-
to-noise ratios exhibited a gradual decreasing trend on 
all contrast weighted images (P < 0.05). Repeat carotid 
intraplaque haemorrhage may be more common in pa-
tients with symptomatic than asymptomatic plaques and 
could represent a possible stimulus for progression of  
atherosclerosis which is stronger than one-time carotid 
intraplaque haemorrhage[55]. 
Contrast-enhanced MRI
Contrast-enhanced MRI (CE-MRI) is typically used to 
perform magnetic resonance angiography (CE-MRA); 
CE-MRA can be supplemented with time-resolved an-
giography, flow measurement, vessel wall imaging, and 
plaque characterisation for a more comprehensive assess-
ment of  vascular diseases[56]. The two types of  contrast 
agent suitable for CE-MRI are the paramagnetic gado-
linium chelates and ultra-small super paramagnetic iron 
oxide (USPIO) particles; however, some patients exhibit 
adverse reactions to these agents. The standard contrast 
agent is Gadolinium bound to a chelate in order to obtain 
a biocompatible compound. Gadolinium is a rare earth 
metal; it has a short T1 time constant, which promotes 
relaxation of  water molecules in its proximity, leading 
to high signal intensity on T1 weighted sequence. After 
injection, the contrast agent initially remains in the vas-
cular space; subsequently Gadolinium-chelate moves into 
the extracellular space, becoming more concentrated in 
areas where the extravascular space is expanded, such as 
in scar tissue, or the fibrous cap. Intravenous Gadolinium 
contrast can be used to improve tissue characterisation 
between the fibrous cap and the lipid core (correlation 
coefficient: 0.87)[57,58] and to identify sites of  neoangio-
genesis (correlation coefficient: 0.67)[59].
Moreover, lipoproteins have been adopted for use as 
effective molecular imaging probes, as ApoA-I has been 
extracted from human plasma and reconstituted with a 
Gadolinium chelate; when injected into ApoE knockout 
mice, a significant accumulation of  this particle was seen 
in the aorta[60]. Further potential of  diagnostic imaging 
of  plaque biological activity includes the visualisation 
of  MMPs expression, as they contribute to destabilizing 
plaques by segmental remodelling; protease expression 
can be studied by employing an activated near-infrared 
fluorescence probe (99mTc-labelled annexin A5)[61] and 
a Gadolinium-coupled matrix metalloprotease inhibi-
tor (MPI) (99mTc-MPI)[62]. Investigations conducted on 
apoE null mice of  different ages, which were adminis-
tered 2 tracers, demonstrated that between 20 and 40 wk 
the aortic lesion area increased, the disease extended into 
the carotids and the MMP expression was greater than 
apoptosis as the disease progressed. Thus, differences 
found in the histology correlated with differences in 
tracer uptake, and the results supported the premise that 
radiolabeled MPI is better than annexin A5 for the imag-
ing of  more advanced disease[63].
USPIO particles are iron-based blood pool agents 
with a strong T1 and T2 shortening effect. USPIOs have 
the combined property of  being taken up by macro-
phages, and of  being visible by CMR, as iron particles 
cause low signal intensity on CMR images. High sen-
sitivity and specificity of  CMR to USPIOs have been 
demonstrated by a surgical trial in which USPIOs were 
administered before and after endarterectomy (P < 0.001, 
sensitivity: 92.5%; specificity: 64%)[64], and USPIO-related 
signal drop out was concordant with plaque inflamma-
tion, as visualised by 18FDG PET (see section below), 
but not necessarily unlinked to the degree of  stenosis[65]. 
Additionally, USPIOs have been used to show a reduc-
tion in carotid plaque morphology in response to inten-
sive cholesterol lowering with statin treatment[66]; none-
theless, this agent (Sinerem® 20 mg/mL) has now been 
withdrawn. Larger microparticles of  iron oxide (4.5 μm 
diameter) have also been constructed to target endothelial 
P-selectin and VCAM-1 adhesion molecules, which allow 
binding to the arterial wall in the early stages of  plaque 
development[67].
IONIZING IMAGING TECHNIQUES
CT and PET are imaging techniques that have to com-
promise with the radioactivity induced by X-ray and 
radionuclides, respectively. Ionizing radiation may in-
terfere with molecule binding and alter DNA and RNA 
transcription, generating free radicals. For instance, radia-
tion doses associated with commonly used CT examina-
tions resemble doses received by individuals in whom an 
increased risk of  cancer was documented[68,69]. In Table 
2, the possibilities of  biological/morphological target 
identification of  each ionizing diagnostic criterion are 
presented, according to the relevant literature.
Electron-beam CT and multiple detector CT
Two types of  CT scanner can be used to assess athero-
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sclerosis: electron-beam CT and multiple detector CT 
(MDCT). The former uses tungsten rings to generate 
X-ray images at 3-mm slice thickness and is used to cal-
culate coronary artery calcium score in the assessment 
and prediction of  cardiovascular risk[70]. Conversely, the 
latter uses a continuously rotating X-ray source able to 
obtain 0.5-mm slices during a single patient breath-hold. 
Intravenous contrast can be used to perform coronary 
angiographic (CTA) imaging in order to extract informa-
tion on atherosclerotic plaques in the coronary arterial 
wall.
Analyses of  CT imaging revealed how the amount 
of  coronary calcium detected was correlated with the 
amount of  coronary atherosclerosis present on histol-
ogy[71], thus artery calcium scoring has been the pre-
dominant method of  risk assessment using CT to date. 
However, the imperative to image the vessel wall, has led 
to an improvement in the use of  CT to perform CTA in 
order to identify Glagov-type outward arterial remodel-
ling (P < 0.01; sensitivity: 100% specificity: 90% com-
pared to intravascular ultrasound (IVUS)[72] and to assess 
soft (non-calcium containing) atherosclerotic plaques. A 
recent study found that patients affected by plaques ac-
companied by positively remodelled coronary segments 
and characterised by CT low attenuation were at higher 
risk of  acute coronary syndrome than were patients with-
out these findings[73]. In younger patients, CTA can detect 
both calcium- and lipid-rich plaques; in elderly patients, 
it allows exclusion of  the presence of  a flow-limiting 
stenosis even if  the calcium burden is high[74]. In addition 
to exquisite delineation of  arterial wall calcium, CT can 
potentially differentiate between lipid-rich and fibrous 
plaque, although the overall specificity is lowered by the 
large overlap in the attenuation values of  these plaque 
components[75].
However, the majority of  clinical research to date has 
been performed employing 64-slice CT scanners; ongo-
ing technical developments are likely to increase the ap-
plicability of  CT in the future. Progressive improvements 
introduced in MDCT imaging include the reduction of  
the potential for cardiac and respiratory motion artefact, 
as well as the introduction of  256- and 512-slice scanners 
aiming to significantly improve the spatial resolution[76,77] 
with potential for fibro-fatty plaque identification[78].
Contrast-enhanced MDCT
Detailed imaging of  plaque morphology can also be per-
formed when an appropriate contrast medium is used: a 
good correlation between contrast-enhanced MDCT (So-
lutrast 300, 300 mgI/mL−1, Altana, Konstanz, Germany) 
and IVUS has been demonstrated in terms of  plaque 
characterisation and volumetric analysis. The mean cross-
sectional areas of  plaque, lumen and external elastic 
membrane, and the degree of  vessel obstruction (per-
centage of  the external elastic membrane cross-sectional 
area occupied by the plaque) determined by IVUS and 
64-slice contrast-enhanced MDCT were highly correlated 
(r = 0.73, r = 0.81, r = 0.88, and r = 0.61, respectively)[79]. 
Additionally, these findings are supported by a study 
investigating the possibility of  constructing a MDCT 
based “plaque map” from a series of  0.4 mm thick cross-
sectional images of  the coronary artery obtained at in-
tervals of  5 mm. Compared with the results for IVUS 
in the analysis of  662 slices of  78 vessels, the “plaque 
map” showed sensitivities of  92%, 87% and 89% in the 
identification of  soft, intermediate and calcified lesions, 
respectively[80]. 
Macrophage accumulation can also be detected by 
means of  iodine-based contrast agent (N1177) in com-
bination with MDCT. The intensity of  the enhancement 
detected with CT in the aortic wall of  rabbits injected 
with N1177 correlated with inflammatory activity evalu-
ated with 18F-FDG PET/CT and macrophage density on 
histology[81].
Newly developed contrast media can also be em-
ployed in the assessment of  plaques using an experimen-
tal CT scanner, such as the spectral CT system, in which 
incident X-rays are divided into six different energy bins 
to achieve multicolour CT imaging. Different compounds 
were imaged in a variety of  phantoms: gold high-density 
lipoprotein nanoparticle contrast agent (Au-HDL) tar-
geting atherosclerosis, an iodine-based contrast agent 
and calcium phosphate[82]. Au-HDL was intravenously 
injected at baseline; the calcium phosphate contrast mate-
rial was injected 24 h later and the CT imaging was then 
performed. Multicolour CT imaging, conducted with the 
spectral CT scanner, allowed differentiation of  Au-HDL, 
iodine-based contrast material, and calcium phosphate 
in the phantoms. Multicolour CT, used in combination 
with Au-HDL, was further studied to evaluate its poten-
tial in characterising macrophage burden, calcification, 
and plaque stenosis in an apolipoprotein E knockout 
(apo E-KO) mouse in vitro model of  atherosclerosis and 
validated against transmission electron microscopy and 
confocal microscopy of  aorta sections[82]. Au-HDL ac-
cumulated in the aortas of  the apo E-KO mice, while the 
MDCT CE-CT PET SPECT 
Morphology features
   Outward Remodelling [72]1 [79]2 -2 -2
   Plaque Burden -2 -2 -2 -2
   Lipid pool [77]1 -2 -2 -2
   Necrotic core -2 -2
Composition
   Fibro-fatty [77]1 [80]2 -1 -2
   Fibrous plaque [77]1 2 -2 -2
   Dense calcium [72]1 2 -2 -2
Biological features
   Inflammation -2 [81]2 [105]1 [103]2
   Macrophage infiltration -2 2 [99,100]2
   Neo-angiogenesis -2 -2 [99]1 -2
Table 2  Plaque feature identification through non-invasive 
diagnostic imaging (using ionizing radiation)
1Limited clinical experience; 2research in progress. MDCT: Multidetector 
computed tomography; CE-CT: Contrast-enhanced computed tomography; 
PET: Positron emission tomography; SPECT: Single proton emission 
tomography.
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iodine-based contrast agent and calcium-rich tissue were 
also co-localized with the vasculature and bones (skeleton) 
(Figure 5). 
Microscopic analysis of  the samples revealed that 
Au-HDL is primarily found in the macrophages; hence, 
multicolour CT was able to image the macrophage bur-
den. An independent review on the above study showed 
that if  the translation of  these studies to humans were 
successful, complete plaque characterisation would be 
possible by means of  a one-in-all scan able to detect, 
simultaneously, plaque stenosis, calcification and inflam-
mation[83]. Although multispectral CT imaging could 
be extremely valuable in addressing inflamed areas, the 
major challenge to be overcome is the high dose of  gold 
particles administered. Specifically, tracer doses, around 
35 g of  Au-HDL for an adult, raise issues regarding the 
safety, bio-disposition, costs and consequent availability 
of  a clinical spectral CT scanner. 
However, the main concern in employing CT-based 
modalities is the radiation dose, which is currently be-
tween 9 and 1 mSv for a retrospectively gated MDCT 
coronary angiogram[84]. Recent technical advances, such as 
the use of  volume scanning (as opposed to helical scan-
ning) allowed a reduction in the effective radiation dose 
by 90% for the average examination[85]. Furthermore, 
the investigative use of  serial MDCT plaque imaging in 
clinical practice is currently under optimization. Despite 
plaque progression being shown in the clinical setting[86], 
it is still unclear how this relates to patient prognosis. 
Conversely, a negative CT coronary angiogram has a pre-
dictive value for coronary artery disease and can avoid 
further invasive coronary angiography for patients at low 
or intermediate risk of  coronary artery disease[87].
PET 
PET and single photon emission CT (SPECT) are able to 
trace tissue metabolic activity by means of  positron emit-
ting isotopes, typically glucose isotopes bind to a tracer 
molecule injected into the subject. The consensus is that 
18-fluorodeoxyglucose (18FDG), the most commonly 
used tracer, uptake is generally greater in symptomatic 
atheromatous plaques than in asymptomatic lesions[88] 
and the arterial 18FDG signal was found to be linked to 
levels of  inflammatory biomarkers[89] and to factors of  
the metabolic syndrome[90].
SPECT and PET differ in several ways; given its bet-
ter spatial resolution (4 to 5 mm vs 1 to 1.6 cm)[91,92] and 
its intrinsic capability to quantify biological processes 
in absolute terms, PET has been used, with 18FDG or 
translocator protein ligands and choline ligands, in most 
of  the human studies on nuclear imaging of  atherosclero-
sis. Nonetheless, specific SPECT ligands have been used 
in order to investigate their capabilities of  probing vari-
ous processes of  atherosclerosis progression and rupture, 
including chemotaxis[93], angiogenesis[94], lipoprotein ac-
cumulation[95], proteolysis[96] and thrombogenicity[97]. For 
these reasons, PET and SPECT have been established 
as important tools for identifying vascular inflammation 
in the inflammatory vasculitides, and for monitoring pa-
tients with inflammatory diseases[98,99].
Specifically, the possibility of  imaging in vivo early and 
developing plaque-like lesions by means of  a C-type atrial 
natriuretic factor (C-ANF) has been investigated[100]. Vul-
nerable lesions are indeed often characterised by vascular 
remodelling and manifest the up-regulation of  natriuretic 
peptide clearance receptors (NPR-Cs) expression both in 
the endothelium and in vascular SMCs (VSMCs); natri-
Figure 5  Example of gold high-density lipoprotein 
nanoparticle contrast agent detection through 
spectral computed tomography. A-C: Spectral com-
puted tomography (CT) images of thorax and abdo-
men in apolipoprotein E knockout (apo E-KO) mouse 
injected 24 h earlier with gold high-density lipoprotein 
nanoparticle contrast agent (Au-HDL); D, E: Spectral 
CT images near bifurcation of aorta in apo E-KO 
mouse injected with Au-HDL and an iodinated emul-
sion contrast agent (Fenestra VC) for vascular imaging 
(reprint with permission)[82].
A B C
D E
Conventional Gold Overlay
Conventional CT image
Aorta
Overlay of gold, iodine, 
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compton image
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uretic peptides have strong antiproliferative and antimigra-
tory effects on VSMCs. C-ANF was functionalised with 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
(DOTA) and labelled with copper-64 (64Cu) then, prior 
to PET scanning, injected in a hypercholesterolaemic rab-
bit bearing atherosclerotic-like lesions. Histopathology 
and immunohistochemistry analyses were performed to 
assess plaque development and NPR-C localisation. 64Cu-
DOTA-C-ANF uptake in the atherosclerotic region was 
imaged by PET, with the highest target-to-background 
ratio (3.59 ± 0.94). PET and immunohistochemistry com-
petitive blocking studies confirmed receptor-mediated 
64Cu-DOTA-C-ANF uptake in the plaque, concluding 
that the tracer may be a promising candidate for in vivo 
PET imaging of  NPR-Cs on atherosclerotic plaques[100]. 
Furthermore, monocyte recruitment can be imaged by 
means of  a radiolabelled peptide (18F-4V), which can be 
internalized by the endothelial cells through VCAM-1-
mediated binding[101].
MMPs are also believed to play a crucial role in plaque 
destabilization; hence the feasibility of  in vivo imaging of  
MMP expression has also been investigated. In particular, 
the results from radiolabelled broad-based MPI adminis-
tered to apoE null and LDLR null mice described the in 
vivo uptake of  a 99mTc-labelled MPI RP805 in aortic ath-
erosclerotic plaque; uptake of  the tracer correlated with 
immunohistochemical staining for macrophages and with 
MMP-2 and MMP-9[102,103]. Furthermore, modifications 
in the signal from the 99mTc-MPI within the lesion can 
be used to tailor therapies, usually statin-based, to reduce 
MMP expression[104].
However, the main limitation of  PET is poor spatial 
resolution; nonetheless, this difficulty has, to a large ex-
tent, been overcome by advances in imaging hardware 
and software that allow PET images to be co-registered 
with another imaging modality with much higher spatial 
resolution (most commonly CT, often in combined PET-
CT scanners)[105]. The first clinical study using PET-CT 
to assess atheromas in vivo included 8 patients presenting 
with angiographic carotid artery stenosis and reporting 
a recent transient ischemic attack (TIA). PET was co-
registered with CT, and plaques were found ipsilaterally 
with respect to the ischemic symptoms in all patients; fur-
thermore, 18FDG accumulated in the ipsilateral plaque, 
significantly more than in the plaque on the contralateral 
side. On the basis of  the histological analysis following ca-
rotid endarterectomy, areas of  18FDG uptake were found 
to correspond to dense macrophage infiltration within 
the plaque[106]. A subsequent larger study confirmed these 
findings and correlated the degree of  18FDG uptake with 
the degree of  macrophage staining in the corresponding 
histological sections[107]. 
PET can also be co-registered with CMR (Figure 6), 
which provides better plaque imaging; requiring two sep-
arate scans, co-registration using anatomical landmarks is 
needed in this case. In the past, the combination of  the 
two modalities has revealed, for patients with recent TIA 
and an ipsilateral high-grade carotid stenosis, an addition-
al ipsilateral lesion with a high level of  18FDG uptake, 
but without high-grade stenosis[108]. 
PET-CT has also been used to assess the effective-
ness of  statin therapy in reducing the level of  inflam-
mation[109]. More challenging is the imaging of  inflamed 
atheroma in the coronary vasculature with 18F-FDG 
due to myocardial uptake of  18F-FDG and the smaller 
size of  the coronary arteries. Nonetheless, the feasibility 
of  PET-CT imaging of  inflamed lesions in the coronary 
vessels has been recently demonstrated, suppressing the 
myocardial 18FDG uptake by administering a high-fat, 
low-carbohydrate diet to the patients[110].
Alternatively, 18F-labelled fluorocholine (FCH) can 
be used to elude 18FDG myocardial uptake[111]. FCH is 
a tracer usually employed to image prostate cancer on 
the basis that activity of  the choline-specific transporter 
increases in proliferating cells. Activated macrophages, 
similar to tumour cells, show enhanced FCH uptake[112], 
and a study conducted on mice demonstrated, for the 
first time, that FCH has a greater sensitivity in detecting 
plaques with respect to FDG (84% vs 64%)[113]. 
INVASIVE IMAGING TECHNIQUES
Diagnostic imaging can be used to closely investigate the 
atherosclerotic lesion due to probe miniaturization which 
allows intravascular imaging of  symptomatic patients, 
undergoing invasive angiography, in order to detect mor-
phological and biological markers of  unstable and vulner-
able plaques, as listed in Table 3.
Intravascular optical coherence tomography 
Studies have revealed that optical coherence tomogra-
phy (OCT) is capable of  differentiating lipid tissue from 
water-based tissues[114]. Furthermore, the thickness of  the 
fibrous cap overlying an atheroma can be demarcated by 
OCT, as demonstrated in the in vitro analysis of  aortic tis-
IVUS VH US-E OCT IVMRI
Morphology features
   Outward remodelling -1 -1 [137]1 [116]1 -1
   Plaque burden [124]1 -1 [137]1 [116]1 -1
   Lipid pool [126]1 [130]1 -2 -1 -1
   Necrotic core [124]1 [131]1 -2 -1 -1
Composition
   Fibro-fatty [131]1 [141]1 [116]1 [146,147]1
   Fibrous plaque [131]1 [141]1 [116]1
   Dense calcium [128]1 [131]1 [138]1 [116]1
Biological features
   Inflammation -2 [57]1 [122]1 -2
   Macrophage infiltration -2 -2 [141]1 [119]1 -2
   Neo-angiogenesis -2 -2 -2 -2 -2
   TFCA -1 -1 -1 [116]1 -2
   TFCA  + MI -2 -2 [137]1 -2 -2
Table 3  Plaque feature identification through invasive 
diagnostic imaging
1Limited clinical experience; 2research in progress. IVUS: Intravascular 
ultrasound; VH: Virtual histology; OCT: Optical coherence tomography; 
US-E: Elastography; IVMRI: Intravascular magnetic resonance imaging; 
MI: Macrophage infiltration; TFCA: Thin fibrous cap atheroma.
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sue[114]. The potential for intravascular assessment of  cul-
prit lesions in the coronary arteries has also been investi-
gated. This procedure could enable detailed measurement 
of  fibrous cap thickness as well as identification of  ero-
sive processes and thrombus formation, as achievements 
in post mortem samples have suggested (Figure 7)[115].
Usually performed only qualitatively via OCT[116], iden-
tification of  plaque components amongst fibrous, calci-
fied and lipid-rich tissues is intended to be supported 
quantitatively by targeting specific optical coefficients, 
such as optical attenuation μt[117], backscatter and extinc-
tion coefficients[118]. OCT can also evaluate the presence 
and quantity of  cellular species typically found in ath-
erosclerotic plaques such as macrophages and smooth 
muscle actin[119]. The feasibility and accuracy of  OCT for 
detecting the frequency and spatial distribution of  TFCA 
has been investigated on coronary arterial segments ex 
vivo; OCT accurately detected TFCA with 90% sensitivity 
and 79% specificity[116].
The use of  OCT, which has a resolution between 4 
and 20 μm, may be advantageous in measuring vulner-
able cap thickness, usually thinner than 65 μm, and re-
cent findings demonstrated that quantitative assessment 
of  plaque components could be feasible in vivo[120]. The 
further diagnostic potential of  OCT imaging can be seen 
in the use of  functionalized magnetofluorescent NPs tar-
geting endothelial markers, such as VCAM-1 which is a 
critical component of  the leukocyte-endothelial adhesion 
cascade regulating the atherogenic process[121]. Cathepsin 
B activated NPs were also used within optical imaging 
methodologies to monitor plaque inflammation in small 
animal in vivo studies[122].
Clearly, the major limitation of  OCT is its invasive-
ness, limiting its application to patients who have already 
been referred for X-ray angiography. Nonetheless, OCT 
remains the imaging technique with the highest spatial 
resolution, suitable for assessing the thickness of  the fi-
brous cap.
Intravascular ultrasound 
US imaging of  arterial disease with magnified detail of  
the plaque has been made possible only since the recent 
expansion of  endovascular techniques and ultrasound 
probe miniaturization, which has led to the rapidly evolv-
ing diagnostic imaging modality known as IVUS[123]. 
IVUS provides real-time, as opposed to offline IB-US 
processing, with cross-sectional images of  the exam-
ined vessel perpendicular to the longitudinal axis of  the 
catheter. Previous studies on the applicability of  IVUS 
in conjunction with coronary angiography demonstrated 
the feasibility of  3D reconstruction of  coronary arteries 
via IVUS, with the motion of  the catheter being tracked 
from bi-planar angiographic images[124]. The latest IVUS 
probes use phased array transducers sited around the tip 
of  a catheter, allowing coaxial and fast exchange cath-
eter configurations with a guide wire. Phased array US 
employs an electronically-controlled current that travels 
around the transducer firing US signals, which are sent 
out in a rotating sweep[125]. An IVUS examination can 
discriminate all three layers of  the arterial wall[126], detect 
the presence of  plaque[127], and can assess atherosclerotic 
disease[128] as well as plaque features, by identifying vul-
nerable or ruptured plaques, Glagov-type outward arte-
rial remodelling[129,130] and the extent of  calcified nodules, 
with variable accuracy depending on the regularity of  
lumen surface (sensitivity 94.1%, specificity 90.3% for 
convex lumen; sensitivity 64.7%, specificity 88.4% for 
irregular lumen)[128]. Monitoring changes in the extent of  
coronary atherosclerosis with IVUS has been increasingly 
employed in clinical trials to assess progression of  the 
pathology, as IVUS is able to generate high-resolution 
Figure 6  Co-registered fluorodeoxyglucose 
positron emission tomography and low-
resolution magnetic resonance images in 
the neck region (arrows). Right carotid is 
indicated (courtesy of Dr. Rudd).
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Figure 7  Measurement of fibrous cap thickness in ruptured plaque using 
optical coherence tomography. Residual fibrous cap was identified as a flap 
between the lumen of the coronary artery and the cavity of plaque, and its thick-
ness was measured at the thinnest part (arrows). Scale bar = 1 mm (courtesy 
of Dr. Kubo).
1 mm
imaging of  the entire thickness of  the coronary artery 
wall permitting evaluation of  the entire burden of  ath-
erosclerotic plaque[131]. The resolution of  IVUS (150 
to 300 μm) may be insufficient to detect thin fibrous 
caps in coronary (50 to 75 μm) or carotid arteries (200 
μm)[129]. However, “virtual histology” (VH) could be real-
ized through IVUS, implementing the spectral analysis 
of  the backscattering US signal to model plaque in three 
dimensions. This approach has been validated in ex vivo 
coronary arteries, and was successful in identifying lipid-
rich necrotic cores, fibro-fatty plaques, and regions of  
calcification (Figure 8) with high accuracy[132-134]; addition-
ally, its application in vivo demonstrated that the angio-
graphic and clinical outcome up to 12 mo after long stent 
placement guided by IVUS was superior to guidance by 
angiography[135]. 
Despite its invasiveness, IVUS facilitates the in vivo 
delineation of  the relative contributions of  the necrotic 
core and fibrous atheroma in unstable lesions. Its clini-
cal potential lies in it being used prior to percutaneous 
intervention in order to inspect and measure vessel size, 
evaluate side-branch anatomy, plaque length and assess 
calcification. Recent studies demonstrated that IVUS 
employed in conjunction with carotid artery stenting 
provided precise disease assessment and efficient surgery 
planning with no adverse events[136]. Although showing 
satisfactory inter-operator reproducibility, the classifica-
tion of  VH still relies on manual border detection and 
needs an improved automatic border detection algorithm 
for the use of  VH IVUS as a diagnostic tool for surgical 
assessment[137].
IVUS can also be employed in elastography (US-E) 
to determine mechanical properties of  the plaque. Elas-
tography reflects the rate of  deformation (strain) of  the 
tissue and can be employed as an index of  mechanical 
stiffness. The lumen is strained between pairs of  US 
detectors that acquire the signal at a certain intraluminal 
pressure and at a slightly different pressure value (± 3 
mmHg)[138,139]. Displacement of  the signals of  the two 
IVUS images is estimated and the strain of  the tissue can 
be calculated by dividing the differential displacement 
(“displacement of  proximal layer” - “displacement of  
distal layer”) by the undeformed distance between the 
two layers. The strain can then be calculated for multiple 
layers and colour-coded into a so-called “elastogram”. 
The elastogram images the radial strain on the arterial 
wall and plaque deformability can be derived for the en-
tire volume (Figure 9). Specifically, US-E showed a high 
sensitivity and specificity (88% and 89%) in identifying 
vulnerable plaques from excised human coronary arter-
ies[140]. Moreover, animal studies demonstrated that elas-
tography is capable of  identifying fibro-fatty and fibrous 
plaques and macrophage infiltration, with high sensitivity 
(93%, 96% and 92%, respectively) and specificity (89%, 
76% and 66%, respectively)[141]. 
Although US-E is able to differentiate fatty from fi-
brous plaques, compared with VH-IVUS, it remains an 
emerging imaging modality, thus prospective studies cor-
relating vulnerable plaques identified by US-E and cardiac 
events are underway[142].
Intravascular MRI
Similar to IVUS, probe miniaturization allowed the devel-
opment of  intravascular MRI (IVMRI) catheters capable 
of  imaging the arterial wall of  the aorta or the coronary 
arteries without external magnets or coils, and the result-
ing signal enabled the differentiation of  lipid-rich and fi-
brotic-rich areas of  the atherosclerotic plaque on the ba-
sis of  differential water diffusion[143-145]. Preliminary ex vivo 
studies demonstrated good agreement between IVMRI 
and histology, with a specificity of  89% and a sensitivity 
of  100%, with spatial resolution of  IVMRI as low as 100 
μm[146]. Regardless of  the limitations due to the necessary 
use of  an occluding balloon and to the mechanical rota-
tion of  the catheter, in vivo data obtained in human iliac 
arteries indicate that IVMRI might be superior to IVUS 
in identifying lipid, fibrous and calcified areas within the 
plaque burden[147].
CONCLUSION
Clinical results obtained by exploiting the capabilities 
derived from efficient plaque imaging show how current 
guidelines for atherosclerosis therapy planning, based 
purely on percentage stenosis, fail to address a significant 
proportion of  culprit lesions. Therefore, medical imag-
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Figure 8  Example of intravascular ultrasound imaging (left), virtual histology (center) and movat pentachrome histology (courtesy of Dr. Nair).
ing is continuously improving towards higher accuracy in 
recognizing in vivo morphological and molecular features 
related to vulnerability. Specifically, identification of  mor-
phological features is more effective with higher spatial 
resolved imaging modalities (Figure 10, top), whereas 
precise biological processes and compound detection is 
achievable independent of  the spatial resolution of  imag-
ing modalities able to trace the specific contrast agent and 
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Figure 9  In vitro intravascular echogram and 
elastogram of a human femoral artery. The elas-
togram reveals that the plaque at 12 o’clock con-
tains a soft core that is covered from the lumen by 
a stiff cap. At 9 o’clock a soft tissue is present at the 
lumen vessel-wall boundary. A different strain was 
found at 9 and 3 o’clock and this difference was not 
present in the echogram[140].
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Figure 10  Spatial resolution and dose-effectiveness of different diagnostic imaging modalities. Minimum spatial resolution required for the identification of the indi-
cated morphological feature of vulnerable atherosclerotic plaque (top); dose effectiveness in the identification of specific biological processes and compound; specific target 
and respective tracer are indicated (bottom). SPECT: Single photon emission computed tomography; PET: Positron emission tomography; CT: Computed tomography; MRI: 
Magnetic resonance imaging; IB-US: Integrated backscatter ultrasonography; IVMRI: Intravascular magnetic resonance imaging; IVUS: Intravascular ultrasound; US-E: 
Intravascular ultrasound employed in elastography; VH: Virtual histology; OCT: Optical coherence tomography; CE-MRI: Contrast-enhanced magnetic resonance imaging; 
CE-CT: Contrast-enhanced computed tomography; CE-US: Contrast-enhanced ultrasonography; FDG: Fluorodeoxyglucose; USPIO: Ultra-small super paramagnetic iron 
oxide; Au-HDL: High-density lipoprotein nanoparticle contrast agent; VCAM: Vascular cell adhesion molecule; NP: Nanoparticle; MPIO: Microparticles of iron oxide.
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is considered highly efficient for minimum agent dose 
administration (Figure 10, bottom). 
Current challenges for atherosclerosis plaque imaging
The in vivo detection of  plaque vulnerability has the po-
tential to become a reality soon, due to the various tech-
niques described in this review, when they are translated 
into the clinical routine. However, their implementation 
is currently limited by the difficulty in resolving minute 
regions of  interest within a much larger field of  view, for 
instance when small coronary vessel diameter is below 
PET and SPECT spatial resolution. Presentation of  the 
information in a quantifiable and easy-to-read manner 
also needs further improvements to achieve effective em-
ployment in the diagnostic paradigm.
Moreover, the correlation between imaging data, the 
risk of  rupture and, eventually, the outcome of  patients 
needs to be reinforced, broadening what was recently 
addressed by VH and IVUS based clinical trials[148,149] 
through the collection of  blood-based markers and di-
verse imaging data. Therefore, novel techniques need to 
be widely available and affordable to allow the success of  
ongoing prospective studies[150] and to provide standard-
ized high-quality image sets for quantitative reference, 
as well as new integrated risk markers for low-risk and 
intermediate-risk population management. 
Future perspective
A summary of  the clinical implementation and research 
stage of  the different imaging modalities is illustrated in 
Figure 11.
Potential advances in image based plaque morphol-
ogy assessment can be seen from the application of  3T 
and 7T MR scanners in clinical practice, as documented 
in a recent study[151] as well as from the implementation 
in real-time of  IB-US methodologies and RF spectral 
analyses. Furthermore, implementation of  micro and 
nanostructured contrast agents, developed to selectively 
enhance specific biological compounds at a molecular 
level, could lead to a substantial reduction in contrast 
agent dose to achieve satisfactory examinations[11,43].
Further improvements in available imaging modalities 
should take account of  the costs that would be incurred 
once implemented and the trade-off  in terms of  diagnos-
tic accuracy (Figure 12); those requiring a catheterization 
procedure are not only highly invasive, hence useful for 
a niche of  symptomatic cases already referred for arterial 
angiography, but are extremely expensive as the catheter-
ization intervention increases the cost of  these imaging 
modalities to 20 times more than US and double that of  
the most expensive non-invasive imaging modality[152]. 
The latter, PET, is a concern due to the radioactive nature 
of  18FDG, as each examination has a radiation exposure 
of  approximately 5 mSv (250 chest X ray equivalents)[153]. 
Therefore, clinical translation of  novel contrast media 
for CT and MRI as well as the development of  innova-
tive sequencing may allow a similar level of  accuracy with 
limited costs; additionally, improvements in CE-US and 
further optimization towards real-time implementation 
of  IB-US analysis will result not only in a drastic reduc-
tion in costs associated with plaque characterisation, but 
also an important reduction in the invasiveness of  such 
diagnostic procedures. For example, although their hu-
man application is still limited, the optical properties of  
contrast media suitable for US imaging are being exten-
sively studied[154-156] aimed at a hybrid imaging modality, 
namely optoacoustic imaging, which could obtain images 
with high optical contrast at high ultrasonic resolution 
in relatively large volumes of  biological tissue[15,157]. The 
use of  NPs combined with a site specific drug delivery 
system is extremely promising for pharmacological and 
gene therapy applications[158] or molecular guided LASER 
or US based interventions[40]. Finally, implementation of  
nanostructured contrast agents will reduce the health 
hazards due to ionizing radiation or radioactive tracers 
and of  those derived from surgical treatments and from 
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Figure 11  Clinical implementation and research status of diagnostic imaging modalities for atherosclerotic plaque characterization. US: Ultrasonography; 
PET: Positron emission tomography; CT: Computed tomography; MRI: Magnetic resonance imaging; OCT: Optical coherence tomography; IVUS: Intravascular ultrasound; 
VH: Virtual histology; US-E: Intravascular ultrasound employed in elastography; CE-US: Contrast-enhanced ultrasonography; IB-US: Integrated backscatter ultrasonogra-
phy; CE-CT: Contrast-enhanced computed tomography; PET-MRI: Positron emission tomography-magnetic resonance imaging; PET-CT: Positron emission tomography-
computed tomography; CE-MRI: Contrast-enhanced-magnetic resonance imaging; IVMRI: Intravascular magnetic resonance imaging.
traditional high dose pharmacological therapies.
Translating in vivo the possibility of  performing high 
resolution imaging and highly accurate reconstruction of  
plaque components distribution, traditionally performed 
on histological specimens, may lead to a completely dif-
ferent approach to atherosclerosis assessment and thera-
peutic planning.
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CE-MRI: Contrast-enhanced magnetic resonance imaging; CT: Computed tomography; US: Ultrasound; SPECT: Single photon emission computed tomography; MRI: 
Magnetic resonance imaging; OCT: Optical coherence tomography; IVUS: Intravascular ultrasound; IVMRI: Intravascular magnetic resonance imaging.
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